- Investing Ideas
- U.S. Pharmaceuticals & Biotech Sustainable Track Record
U.S. Pharmaceuticals & Biotech Sustainable Track Record
Results
12
Companies which have reinvested earnings to sustain 10% yearly growth over 5 years.
12 companies
CorMedix
Market Cap: US$599.4m
A biopharmaceutical company, focuses on developing and commercializing therapeutic products for life-threatening diseases and conditions in the United States.
CRMD
US$7.85
7D
-8.7%
1Y
-33.4%
Protalix BioTherapeutics
Market Cap: US$189.3m
A biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system.
PLX
US$2.33
7D
7.4%
1Y
57.4%
Rigel Pharmaceuticals
Market Cap: US$722.3m
A biotechnology company, develops and provides therapies that enhance the lives of patients with hematologic disorders and cancer in the United States.
RIGL
US$39.12
7D
9.9%
1Y
109.1%
Aurinia Pharmaceuticals
Market Cap: US$2.2b
A biopharmaceutical company, engages in delivering therapies to people living with autoimmune diseases with high unmet medical needs in the United States and Japan.
AUPH
US$16.97
7D
-5.1%
1Y
126.9%
Medpace Holdings
Market Cap: US$15.3b
Provides clinical research-based drug and medical device development services in North America, Europe, Asia, South America, Africa, and Australia.
MEDP
US$529.59
7D
11.9%
1Y
64.9%
ACADIA Pharmaceuticals
Market Cap: US$4.3b
A biopharmaceutical company, focuses on the development and commercialization of medicines for neurological and rare disease in North America.
ACAD
US$25.30
7D
11.9%
1Y
18.4%
Exelixis
Market Cap: US$13.6b
An oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States.
EXEL
US$54.41
7D
6.0%
1Y
24.7%
TG Therapeutics
Market Cap: US$7.8b
A commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally.
TGTX
US$54.94
7D
2.5%
1Y
51.4%
Catalyst Pharmaceuticals
Market Cap: US$3.9b
A commercial-stage biopharmaceutical company, focuses on developing and commercializing medicines for patients living with rare diseases in the United States.
CPRX
US$31.43
7D
0.1%
1Y
48.3%
Eli Lilly
Market Cap: US$1.1t
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally.
LLY
US$1,199.43
7D
8.3%
1Y
54.6%
Earth Science Tech
Market Cap: US$46.1m
Together with its subsidies, focuses on health and wellness industry.
ETST
US$0.17
7D
6.3%
1Y
-15.1%
CapForce
Market Cap: US$222.9m
A precision medicine company, develops and commercializes molecular microbiology solutions for life threatening infectious diseases in the United States and internationally.
CFOR
US$16.50
7D
716.8%
1Y
246.6%